The present invention relates to a hydrazinopurine compound or triazolopurine compound represented by one of the general formulas shown below (wherein R1, R3, R4, R6, R8, R10and R12each represent a hydrogen atom or an alkyl group, and R2, R5, R7, R9, R11and R13each represent a hydrogen atom, an alkyl group or an aryl group), and also relates to a xanthine oxidase-inhibiting composition or a pharmaceutical composition containing the compound as an active ingredient, and particularly to a pharmaceutical composition for preventing against or treating hyperuricemia, gout and other disorders caused by hyperuricemia.本發明係關於下列通式(式中，R1、R3、R4、R6、R8、R10及R12表示氫原子或烷基，R2、R5、R7、R9、R11及R13表示氫原子、烷基或芳基)代表之肼基嘌呤化合物或三唑嘌呤化合物及含有該化合物作為有效成分之黃嘌呤氧化酶抑制用組成物、醫藥用組成物，尤其關於用於預防或治療高尿酸血症、痛風、及起因於高尿酸血症之病症之醫藥用組成物。
